
Pfizer PFE
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
5.68 B |
Market Cap[1] |
$ 171 B |
EBITDA (LTM) |
$ 6.59 B |
P/E (LTM) |
20.766423 |
P/S (LTM) |
2.583636 |
EPS (LTM) |
1.37 |
Pfizer is a global pharmaceutical company that has been in operation for over 170 years. The company is headquartered in New York City and has a presence in over 150 countries worldwide. Pfizer's mission is to discover, develop, and deliver innovative medicines and vaccines that improve the lives of people around the world.
Pfizer has a diverse portfolio of products that address a range of health conditions, including cardiovascular disease, oncology, inflammation, immunology, and rare diseases. Some of the company's most well-known products include Lipitor, Viagra, and Lyrica.
In addition to developing new treatments, Pfizer is committed to improving access to healthcare for people in need. The company has established partnerships with governments, non-governmental organizations, and healthcare providers to expand access to its medicines and vaccines.
Pfizer is also dedicated to sustainability and reducing its environmental impact. The company has set ambitious goals to reduce greenhouse gas emissions, water consumption, and waste generation across its operations.
As a leading pharmaceutical company, Pfizer is constantly innovating and adapting to meet the changing needs of patients and healthcare providers. With a focus on research and development, access to healthcare, and sustainability, Pfizer is poised to continue making a positive impact on global health for years to come.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market | ||
|
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | ||
|
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | ||
|
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market | ||
|
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | ||
|
Exicure
XCUR
|
$ 1.05 | -7.08 % | $ 6.61 M | Nasdaq Capital Market | ||
|
Cellectis S.A.
CLLS
|
$ 0.98 | 0.51 % | $ 98.3 M | Nasdaq Global Market | ||
|
AbCellera Biologics
ABCL
|
$ 11.82 | 3.96 % | $ 3.53 B | Nasdaq Global Select Market | ||
|
Arrowhead Pharmaceuticals
ARWR
|
$ 58.02 | -0.58 % | $ 7.76 B | Nasdaq Global Select Market,SPB | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 55.95 | -1.2 % | $ 10.7 B | Nasdaq Global Select Market,SPB | ||
|
Celldex Therapeutics
CLDX
|
$ 29.25 | 0.97 % | $ 1.94 B | Nasdaq Global Select Market | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.67 | 1.38 % | $ 44.8 M | Nasdaq Capital Market | ||
|
Jaguar Health
JAGX
|
$ 2.04 | -5.12 % | $ 4.76 M | Nasdaq Capital Market | ||
|
Protalix BioTherapeutics
PLX
|
$ 2.55 | -0.58 % | $ 200 M | NYSE American | ||
|
uniQure N.V.
QURE
|
$ 22.43 | -2.94 % | $ 1.29 B | Nasdaq Global Select Market | ||
|
Stoke Therapeutics
STOK
|
$ 25.04 | -2.57 % | $ 1.48 B | Nasdaq Global Select Market,SPB | ||
|
Xencor
XNCR
|
$ 25.18 | -2.55 % | $ 1.87 B | Nasdaq Global Select Market,SPB | ||
|
Annexon
ANNX
|
$ 3.75 | -1.57 % | $ 582 M | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 1.78 | -2.73 % | $ 2.93 M | NYSE American | ||
|
Incyte Corporation
INCY
|
$ 115.71 | -1.04 % | $ 22.6 B | Nasdaq Global Select Market,SPB | ||
|
Mesoblast Limited
MESO
|
$ 12.28 | -2.15 % | $ 14.8 B | Nasdaq Global Select Market | ||
|
MeiraGTx Holdings plc
MGTX
|
$ 9.21 | -5.73 % | $ 741 M | Nasdaq Global Select Market | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 523.93 | -2.1 % | $ 134 B | Nasdaq Global Select Market,SPB | ||
|
Abeona Therapeutics
ABEO
|
$ 4.4 | -1.57 % | $ 233 M | Nasdaq Capital Market | ||
|
AbbVie
ABBV
|
$ 285.64 | 0.24 % | $ 505 B | NYSE,SPB | ||
|
AIM ImmunoTech
AIM
|
$ 0.16 | -4.11 % | $ 259 K | NYSE American | ||
|
Akebia Therapeutics
AKBA
|
$ 0.57 | 0.84 % | $ 147 M | Nasdaq Global Market | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.2 | -0.24 % | $ 805 M | Nasdaq Global Select Market | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 19.73 | -2.86 % | $ 3.32 B | Nasdaq Global Select Market,SPB | ||
|
ADC Therapeutics SA
ADCT
|
$ 1.44 | -9.72 % | $ 183 M | NYSE | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 25.51 | 4.51 % | $ 3.87 B | Nasdaq Global Select Market,SPB | ||
|
EyePoint Pharmaceuticals
EYPT
|
$ 0.4 | -5.51 % | $ 29.3 K | Nasdaq Global Market | ||
|
Seagen
SGEN
|
- | - | $ 42.2 B | Nasdaq Global Select Market,SPB | ||
|
Agios Pharmaceuticals
AGIO
|
$ 37.0 | -0.51 % | $ 2.14 B | Nasdaq Global Select Market,SPB | ||
|
Oncternal Therapeutics
ONCT
|
- | -24.12 % | $ 1.56 M | Nasdaq Capital Market | ||
|
Iterum Therapeutics
ITRM
|
- | - | $ 591 K | Nasdaq Global Select Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Achieve Life Sciences
ACHV
|
$ 6.49 | -0.15 % | $ 283 M | Nasdaq Capital Market | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
Geron Corporation
GERN
|
$ 1.12 | -0.88 % | $ 747 M | Nasdaq Global Select Market | ||
|
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | ||
|
Aldeyra Therapeutics
ALDX
|
$ 0.65 | 0.68 % | $ 39 M | Nasdaq Global Select Market | ||
|
Gilead Sciences
GILD
|
$ 156.04 | -0.73 % | $ 194 B | Nasdaq Global Select Market,SPB | ||
|
Genmab A/S
GMAB
|
$ 43.79 | 9.48 % | $ 2.83 B | Nasdaq Global Select Market | ||
|
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | ||
|
ImmunoGen
IMGN
|
- | - | $ 7.92 B | Nasdaq Global Select Market | ||
|
Galectin Therapeutics
GALT
|
$ 3.19 | -5.62 % | $ 204 M | Nasdaq Global Select Market | ||
|
Genprex
GNPX
|
$ 1.81 | -8.59 % | $ 1.69 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.